Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 6/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.38 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | PLK4 | O00444 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682108 | 0.88 | CYP2D6 (0.44) | PAK4AURKANTRK1PLK4MAP4K4 | |
| SCHEMBL16675897 | 0.84 | PLK4 (0.40) | PAK4NTRK1PLK4JAK3 | |
| SCHEMBL16675906 | 0.82 | NPC1 (0.36) | PAK4AURKBNTRK1PLK4 | |
| SCHEMBL16675898 | 0.81 | NPC1 (0.39) | PAK4AURKAAURKBRETNTRK1 | |
| SCHEMBL16675894 | 0.81 | RAB9A (0.39) | AURKAAURKBRETATMLCK | |
| SCHEMBL16675955 | 0.80 | GSK3B (0.43) | PAK4NTRK1PLK4MAP4K4ATM | |
| SCHEMBL16675932 | 0.80 | EGFR (0.42) | PAK4AURKAAURKBAURKCRET | |
| SCHEMBL16675904 | 0.79 | GRM4 (0.40) | RETNTRK1PLK4MAP4K4LCK | |
| SCHEMBL16675917 | 0.78 | NPY5R (0.43) | PAK4AURKAAURKBRETNTRK1 | |
| SCHEMBL16675910 | 0.78 | AURKA (0.41) | AURKAAURKBAURKCRETLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | PAK4 3061/4885AURKA 1571/4885AURKB 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.